Successful Lorlatinib Rechallenge After Severe Drug-Induced Psychosis in ALK-Positive Metastatic NSCLC: A Case Report

Successful Lorlatinib Rechallenge After Severe Drug-Induced Psychosis in ALK-Positive Metastatic NSCLC: A Case Report

Neurocognitive adverse events (NAEs) have been reported in up to 60% of patients on lorlatinib, a potent central nervous system–active ALK inhibitor. Manifestations may include psychotic, mood, speech, and cognitive symptoms. Current guidance recommends permanent discontinuation of lorlatinib in cas...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JTO clinical and research reports 2024-07, Vol.5 (7), p.100689, Article 100689
Hauptverfasser: John, Alexius, Vick, Joanna, Sarker, Sarah, Middleton, Elizabeth, Cartwright, Elizabeth, Manickavasagar, Thubeena, McMahon, David, Tokaca, Nadza, Popat, Sanjay
Format: Artikel
Sprache:eng
Schlagworte:
Adverse event
ALK
Case Report
Lorlatinib
Non–small cell lung cancer
Psychosis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Neurocognitive adverse events (NAEs) have been reported in up to 60% of patients on lorlatinib, a potent central nervous system–active ALK inhibitor. Manifestations may include psychotic, mood, speech, and cognitive symptoms. Current guidance recommends permanent discontinuation of lorlatinib in cases of grade IV NAEs. Here, we report a case of successful rechallenge of dose-reduced lorlatinib after recovery of grade IV psychosis in a patient with ALK-positive NSCLC.
ISSN:2666-3643
2666-3643
DOI:10.1016/j.jtocrr.2024.100689